Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 8, August, p. 943–948

doi: 10.17219/acem/121006

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Evaluation of serum human epididymis protein 4 in patients with relapsing-remitting multiple sclerosis

Bożena Adamczyk1,A,B,C,D, Robert Partyka2,A,B, Monika Adamczyk-Sowa1,E,F, Krzysztof Wierzbicki1,A, Paweł Sowa3,A, Danuta Kokocińska2,A

1 Department of Neurology in Zabrze, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

2 Department of Anesthesiology, Intensive Care and Emergency Medicine Ward, St. Barbara’s Provincial Specialist Hospital in Sosnowiec, Medical University of Silesia, Katowice, Poland

3 Department of Laryngology in Zabrze, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

Abstract

Background. So far, little is known about the properties of human epididymis protein 4 (HE4) in multiple sclerosis (MS). This type 4 glycoprotein belongs to a family of genes encoding proteins whose expression is associated with the process of spermatogenesis in the epididymis. The biological function of HE4 is not fully understood. Overexpression of HE4 has been found in several malignant tumors, particularly in ovarian cancer, as well as in mesothelioma, lung, endometrial, breast, and kidney cancers.
Objectives. To evaluate serum HE4 in patients with relapsing-remitting multiple sclerosis (RRMS) as compared to healthy controls.
Material and Methods. Fifty patients with RRMS undergoing first-line immunomodulatory treatment were enrolled in the prospective study. We analyzed correlations between serum HE4 levels and gender, age, disease duration, the Expanded Disability Status Scale (EDSS), annualized relapse rate (ARR), and magnetic resonance imaging (MRI) lesions.
Results. The patients from the study group had higher concentrations of HE4 than the subjects from the control group. Patients with EDSS > 2 had significantly higher concentrations of HE4. Positive correlations were found between HE4 concentrations and age as well as between HE4 concentrations and disease duration. No significant correlations were found between HE4 concentrations and EDSS or between HE4 concentrations and ARR.
Conclusion. The results of the study indicate a novel aspect of the HE4 protein in the pathomechanisms of MS.

Key words

multiple sclerosis, autoimmune diseases, biomarker, human epididymis protein 4, relapsing-remitting multiple sclerosis

References (36)

  1. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45(2):350–357.
  2. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999;238(2):375–385.
  3. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695–3700.
  4. Jia LT, Zhang YC, Li J, Tian Y, Li JF. The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer. Clinical Transl Oncol. 2016;18(3):233–239.
  5. Li J, Chen H, Mariani A, et al. HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines. Int J Mol Sci. 2013;14(3):6026–6043.
  6. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19(6):847–853.
  7. Moore RG, Miller MC, Steinhoff MM, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012;206(4):351.e1–e8.
  8. Zhang M, Zhao B, Xie J, Liang Y, Yang Z. Serum human epididymis protein 4 is associated with renal function and diabetic kidney disease in patients with type 2 diabetes mellitus. Biomed Res Int. 2019;2019:4831459.
  9. Gasiorowska E, Kluz T, Lipski D, Warchol W, Tykarski A, Nowak-Markwitz E. Human epididymis protein 4 (HE4) reference limits in Polish population of healthy women, pregnant women, and women with benign ovarian tumors. Dis Markers. 2019;2019:3890906.
  10. Piek A, Meijers WC, Schroten NF, Gansevoort RT, de Boer RA, Sillje HH. HE4 serum levels are associated with heart failure severity in patients with chronic heart failure. J Card Fail. 2017;23(1):12–19.
  11. Takasaki T, Hagihara K, Satoh R, Sugiura R. More than just an immunosuppressant: The emerging role of FTY720 as a novel inducer of ROS and apoptosis. Oxid Med Cell Longev. 2018;2018:4397159.
  12. Adamczyk B, Adamczyk-Sowa M. New insights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis. Oxid Med Cell Longev. 2016;2016:1973834.
  13. Fiorini A, Koudriavtseva T, Bucaj E, et al. Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: The spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PloS One. 2013;8(6):e65184.
  14. Mossakowski AA, Pohlan J, Bremer D, et al. Tracking CNS and systemic sources of oxidative stress during the course of chronic neuro­inflammation. Acta Neuropathol. 2015;130(6):799–814.
  15. van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta. 2011;1812(2):141–150.
  16. Witherick J, Wilkins A, Scolding N, Kemp K. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis. 2010;2011:164608.
  17. Dringen R. Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal. 2005;7(9–10):1223–1233.
  18. Brenk A, Bodzek P, Balis M, Barbachowska A, Janosz I, Olejek A. Usefulness of HE4 protein in differentiation of pelvic masses in woman. Prz Menopauzalny. 2019;18(1):27–32.
  19. Li X, Gao Y, Tan M, et al. Expression of HE4 in endometrial cancer and its clinical significance. Biomed Res Int. 2015;2015:437468 [Erratum in: Corrigendum to “Expression of HE4 in endometrial cancer and its clinical significance”. Li X, Gao Y, Tan M, Zhuang H, et al. Biomed Res Int. 2018;2018:6795629. doi:10.1155/2018/6795629].
  20. Luo J, Wang F, Wan J, et al. Serum human epididymis secretory protein 4 as a potential biomarker of renal fibrosis in kidney transplantation recipients. Clin Chim Acta. 2018;483:216–221.
  21. Nowak M, Janas L, Stachowiak G, Stetkiewicz T, Wilczynski JR. Current clinical application of serum biomarkers to detect ovarian cancer. Prz Menopauzalny. 2015;14(4):254–259.
  22. Dong C, Liu P, Li C. Value of HE4 combined with cancer antigen 125 in the diagnosis of endometrial cancer. Pak J Med Sci. 2017;33(4):1013–1017.
  23. Uslu B, Dogan S, Ozdem S, Simsek T. Serum concentrations of HE4 and Ca125 in uncomplicated pregnancies: A longitudinal study. J Obstet Gynaecol. 2020; 40(1):70–76.
  24. Avila M, Bansal A, Culberson J, Peiris AN. The role of sex hormones in multiple sclerosis. Eur Neurol. 2018;80(1–2):93–99.
  25. Neto LO, Gromisch ES, Sloan J, Tyry T, Foley FW. Sex differences in predictors of illness intrusiveness in persons with multiple sclerosis. Qual Life Res. 2019;28(2):389–397.
  26. Dewan R, Dewan A, Jindal M, Bhardawaj M. Diagnostic performance of serum human epididymis protein 4 (HE4) for prediction of malignancy in ovarian masses. Asian Pac J Cancer Prev. 2019;20(4):1103–1108.
  27. Lokich E, Singh RK, Han A, et al. HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation. Sci Rep. 2014;4:5500.
  28. Kant K, Tomar AK, Sharma P, Kundu B, Singh S, Yadav S. Human epididymis protein 4 quantification and interaction network analysis in seminal plasma. Protein Pept Lett. 2019;26(6):458–465.
  29. Nowicka-Bauer K, Lepczynski A, Ozgo M, et al. Sperm mitochondrial dysfunction and oxidative stress as possible reasons for isolated asthenozoospermia. J Physiol Pharmacol. 2018;69(3). doi:10.26402/jpp.2018.3.05
  30. Ren Y, Xie J, Lin F, et al. Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus: A prospective cohort study. Int Immunopharmacol. 2018;60:189–193.
  31. James NE, Cantillo E, Oliver MT, et al. HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells. Clin Exp Immunol. 2018;193(3):327–340.
  32. James NE, Oliver MT, Ribeiro JR, et al. Human epididymis secretory protein 4 (HE4) compromises cytotoxic mononuclear cells via inducing dual specificity phosphatase 6. Front Pharmacol. 2019;10:216.
  33. Volpe VO, Klufas DM, Hegde U, Grant-Kels JM. The new paradigm of systemic therapies for metastatic melanoma. J Am Acad Dermatol. 2017;77(2):356–368.
  34. Shen Y, Wang Y, Jiang X, et al. Preparation and characterization of a high-affinity monoclonal antibody against human epididymis protein-4. Protein Expr Purif. 2018;141:44–51.
  35. Wang L, Sun Y, Cai X, Fu G. The diagnostic value of human epididymis protein 4 as a novel biomarker in patients with renal dysfunction. Int Urol Nephrol. 2018;50(11):2043–2048.
  36. Zhang M, Yuan L, Yao F, et al. Human epididymis protein 4 concentration is not associated with liver fibrosis and cirrhosis in a case control study. Clin Chim Acta. 2018;484:213–217.
© Wroclaw Medical University